{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-23-000013","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.674645+00:00","generated_at":"2026-06-17T14:56:09.467192+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acumen reports FY2022 net loss $42.9M; Phase 1 ACU193 enrollment completed, topline Q3 2023","bullets":["Cash, cash equivalents and marketable securities of $193.4M as of Dec 31, 2022, expected to fund operations through 2025.","Net loss of $42.9M for FY2022 vs $100.6M in 2021 (which included $81.2M non-cash charge).","Phase 1 INTERCEPT-AD trial of ACU193 in early Alzheimer's completed enrollment Feb 2023; topline data expected Q3 2023.","Protocol amendment reduced cohort 7 dose to 25 mg/kg Q2W after blinded PK/SA, 2 asymptomatic ARIA-E cases noted.","FDA granted Fast Track designation for ACU193 in Oct 2022; Derrell Porter, M.D. joined board in Jan 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-23-000013","json":"https://secwatch.observer/filing/0001576885-23-000013.json","markdown":"https://secwatch.observer/filing/0001576885-23-000013.md","text":"https://secwatch.observer/filing/0001576885-23-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000013/0001576885-23-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000013/abos-20230327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T14:56:09.467192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20cb682eb677b515333299f7ed45ae7229b0d48a","claim":"Acumen Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 27, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000013/0001576885-23-000013-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}